TechBio Talks

In this episode of TechBio Talks, host Najat Khan, PhD, CEO and President of Recursion, talks to Dr. Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital, about how artificial intelligence and clinical data are converging to transform the measurement of human physiology and disease.
Morgan is a physician, medical geneticist, and investor who has spent nearly a decade backing category-defining companies spanning diagnostics, therapeutics, and care delivery.
They discuss how AI is reshaping the fundamentals of biotech value creation, the vital concept of "modality market fit" for matching therapeutic architectures to patient tolerance, and why the ultimate moat in AI drug discovery is closing the loop between the wet lab, dry lab, and the clinic. Their conversation also covers how recasting medicine as an information science can collapse the barrier between scientific discovery and patient care delivery.

Chapters:
00:00 Introduction
00:57 The Role of Medical Geneticists in Healthcare
03:47 Investing: A Dual Perspective
04:46 Fundamentals of Biotech Value Creation
08:43 Private vs. Public Markets & Discontinuous Tech
12:00 Building the Ultimate Data Moat
13:43 AI as Measurement Tool in Healthcare
18:10 Unlocking Clinical Biobanks
20:42 Precision Therapy & Early Patient Selection
23:48 Defining Modality Market Fit
26:45 Designing for the Patient Experience
29:35 Medicine as an Information Science
31:42 Root Cause Analysis in Medicine and Innovation
33:42 Closing

Recursion CEO and President Najat Khan talks to award-winning journalist, filmmaker, podcaster, and co-founder of Stand Up to Cancer, Katie Couric about their personal motivations; the current state of AI drug discovery; and exciting proof points like Recursion’s potential first-in-disease treatment for the rare disease familial adenomatous polyposis (FAP).

In this episode of TechBio Talks, host Najat Khan, PhD, incoming CEO and President of Recursion, talks to Amy Abernethy, MD, PhD, cofounder of Highlander Health, about how structured, analyzable, real-world data is transforming healthcare and medicine.
Amy is a physician, innovator, and executive who has pioneered oncology real-world evidence generation to address gaps in patient care and access. 
They discuss the three “waves” of real-world data leading to today’s multimodal data; how that real-world data ties into patients’ longitudinal health story; and the difference between real-world data and real-world evidence. And they dive into how this data is driving major innovative shifts to improve clinical trials and drug discovery. 

⏱️ TIMESTAMPS ⏱️ 
(00:00) Introduction.
(01:47) Defining Real-World Data (RWD) & Real-World Evidence (RWE): The difference between data as a byproduct of care and analyzed evidence.
(03:16) The Three Waves of RWD: From claims data to EHRs, and now multimodal, longitudinal data (genomics, imaging).
(05:49) Use Cases for RWE: Telling the story of what happened (retrospective) vs. planning for the future (clinical trial design).
(06:38) RWE in Drug Discovery: Combining deep biological data with clinical phenotypes to find new targets.
(09:14) Strategic Shift in Pharma: Moving RWE from a "replacement product" to a core strategic asset across the entire R&D lifecycle.
(11:06) Regulatory Evolution: How FDA guidance on data quality and curation is enabling broader RWE adoption.
(14:25) The Evidence Accelerator: How rapid-cycle meetings with the FDA during COVID-19 built regulatory familiarity with RWE.
(16:18) Introducing Highlander Health: A dual-model approach (non-profit institute + for-profit investment arm) to accelerate clinical research.
(21:48) AI’s Role in Evidence Generation: Using AI for data curation, study design optimization, and patient recruitment.
(24:41) The "Mantra": AI requires high-quality data; we must go back to the roots of getting the data right.
(27:47) What to Watch For: Disciplined, LLM-enabled data curation and the rise of prospective-retrospective hybrid study designs.

The third episode of TechBio Talks features host Chris Gibson in conversation with leading AI investor Nathan Benaich of Air Street Capital. Learn about the evolving landscape of AI in drug discovery, the biggest trends identified in Nathan’s new State of AI Report, and what AI investors are looking for, now and in the future.

In the second episode of TechBio Talks, host Chris Gibson talks to Anne Carpenter, Institute Scientist and Imaging Platform Senior Director at the Broad Institute of MIT and Harvard, a pioneer in image-based profiling, who played a key role in Recursion’s origin story.  
Anne talks about her early discovery that phenomics-based profiling could be as powerful as mRNA profiling; how she decides what data to make by determining the problems she can solve well; how these tools can be deployed to produce safer chemicals; the critical role of open science in advancing new technologies; and why the race to the virtual cell “is more like a mosh pit.” 

⏱️ Timestamps:
00:00: Welcome to TechBio Talks
02:33: The dinner conversation that helped lay the foundation for Recursion
03:06: Discovering that cell morphology could be as powerful as mRNA profiling
05:32: Behind the open-source tool, CellProfiler
06:21: The importance of relevant biology
07:21: In drug discovery, framing the problem is the real bottleneck
08:55: Which types of data are most important for drug discovery
10:52: Why we need open data
12:30: What it’s like to see others utilize and advance her technology
14:02: How the virtual cell race is “more like a mosh pit”
15:27: Evolving the definition of the virtual cell 
17:38: From systemization to major industry shift
18:51: Anne’s “big bold bet”
20:48: The proposed cost to test existing medicines against rare diseases
22:29: Parting thoughts: “If you are interested in data sciences and you're tired of mRNA profiles – check out image-based data”